The Impact of Geographic Variations in Treatment on Outcomes in Ovarian Cancer

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, Claes G. Tropé, Frédéric Amant et al. · New England Journal of Medicine · 2010 · 2.5K citations · Full text

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

William E. Winter, G. Larry Maxwell, Chunqiao Tian et al. · Journal of Clinical Oncology · 2007 · 839 citations · Full text

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2006 · 746 citations · Full text

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

The Lancet · 2002 · 557 citations

Oncology, Medicine, Single-agent Carboplatin +7

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma

M.J.A. Engelen, Henrike E. Kos, Pax H.B. Willemse et al. · Cancer · 2005 · 304 citations · Full text